Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ).
Shandong Xinhua Pharmaceutical Company Limited has announced that it has received the Drug Registration Certificate for its Lidocaine and Prilocaine Cream from the National Medical Products Administration. This approval marks a significant step for the company, as it allows the product to be marketed and sold, potentially enhancing its market position and offering new opportunities for growth in the pharmaceutical industry.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in China, specializing in the production of various pharmaceutical products. The company focuses on the development and manufacturing of prescription drugs, with a market focus on domestic production.
Average Trading Volume: 2,013,645
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.77B
Learn more about 0719 stock on TipRanks’ Stock Analysis page.